Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Vivek Reddy Added: 1 year ago
EHRA 24 - We interview Dr Vivek Reddy (Icahn School of Medicine at Mount Sinai, US) on a first-in-human clinical trial of a novel conformable "single-shot" pulsed field ablation (PFA) catheter for pulmonary vein isolation (PVI).This single arm trial aimed to assess the safety and efficacy of PVI using an 8Fr PFA catheter (SpherePVI, Affera Inc) in 30 patients across three centers.Interview… View more
Author(s): Kenneth Ellenbogen Added: 6 months ago
A new policy statement released by HRS underscores the importance of continual training and education for electrophysiologists performing catheter ablation of atrial fibrillation (AF).In this short interview, Dr Kenneth Ellenbogen (VCU School of Medicine, US) discusses the key recommendations within this policy statement to ensure a strong electrophysiology base and skillset to achieve the best… View more
Author(s): Yury Malyshev Added: 1 year ago
AF Symposium 24 — Dr Yury Malyshev (Mount Sinai Hospital, US) joins us to discuss the findings from three studies focusing on the long-term effects of pulsed-field ablation (PFA) on coronary arteries.QuestionsWhat is known currently about the effect of PFA in Coronary Arteries? What is the importance of this topic?What was the study design and cohort?What are the key findings?Who are the take… View more
Author(s): Kazuya Hosokawa , Abe Kotaro Added: 1 year ago
AHA 2023 — Dr Kazuya Hosokawa and Dr Abe Kotaro (Kyushu University Hospital, JP) join us to share the findings of the KABUKI trial (NCT04730037). The aim of KABUKI (Daiichi Sankyo) is to assess whether edoxaban, a direct factor Xa inhibitor, is noninferior to warfarin in preventing worsening of chronic thromboembolic pulmonary hypertension (CTEPH).This investigator-initiated, multicenter, phase 3… View more